ARAgnieszka Romanik

Agnieszka Romanik

*This is an algorithmically generated author record based on publicly available information.

Agnieszka Romanik has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment

    by Diana Mikiewicz, Natalia Łukasiewicz, Marcin Zieliński, Violetta Cecuda-Adamczewska, Anna Bierczyńska-Krzysik, Agnieszka Romanik-Chruścielewska, Małgorzata Kęsik-Brodacka


  • Open Access

    Correction: A novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodies

    by Violetta Sączyńska, Agnieszka Romanik, Katarzyna Florys, Violetta Cecuda-Adamczewska, Małgorzata Kęsik-Brodacka, Krzysztof Śmietanka, Monika Olszewska, Katarzyna Domańska-Blicharz, Zenon Minta, Bogusław Szewczyk, et al.

    [This corrects the article DOI: 10.1371/journal.pone.0172008.].

  • Open Access

    Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties – From an efficient E. coli expression system to a pharmaceutical formulation

    by Diana Mikiewicz, Anna Bierczyńska-Krzysik, Agnieszka Sobolewska, Dorota Stadnik, Monika Bogiel, Monika Pawłowska, Anna Wójtowicz-Krawiec, Piotr A Baran, Natalia Łukasiewicz, Agnieszka Romanik-Chruścielewska, et al.

    The discovery of insulin led to a revolution in diabetes management. Since then, many improvements have been introduced to insulin preparations. The availability of molecular genetic techniques has enabled the creation of insulin analogs by changing the structure of the native protein in order to improve the therapeutic properties. A new expression vector pIBAINS for production of four recombinant human insulin (INS) analogs (GKR, GEKR, AKR, SR) was constructed and overexpressed in the new E. coli 20 strain as a fusion protein with modified human superoxide dismutase (SOD). The SOD gene was used as a signal peptide to enhance the expression of insulin. SOD::INS was manufactured in the form of insoluble inclusion bodies. After cleavage of the fusion protein with trypsin, the released insulin analogs were refolded and purified by reverse-phase high performance liquid chromatography (RP-HPLC). Elongation of chain A, described here for the first time, considerably improved the stability of the selected analogs. Their identity was confirmed with mass spectrometric techniques. The biological activity of the insulin derivatives was tested on rats with experimental diabetes. The obtained results proved that the new analogs described in this paper have the potential to generate prolonged hypoglycemic activity and may allow for even less frequent subcutaneous administration than once-a-day. When applied, all the analogs demonstrate a rapid onset of action. Such a combination renders the proposed biosynthetic insulin unique among already known related formulations.


  • Open Access

    A novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodies

    by Violetta Sączyńska, Agnieszka Romanik, Katarzyna Florys, Violetta Cecuda-Adamczewska, Małgorzata Kęsik-Brodacka, Krzysztof Śmietanka, Monika Olszewska, Katarzyna Domańska-Blicharz, Zenon Minta, Bogusław Szewczyk, et al.

    The highly pathogenic (HP) H5N1 avian influenza viruses (AIVs) cause a mortality rate of up to 100% in infected chickens and pose a permanent pandemic threat. Attempts to obtain effective vaccines against H5N1 HPAIVs have focused on hemagglutinin (HA), an immunodominant viral antigen capable of eliciting neutralizing antibodies. The vast majority of vaccine projects have been performed using eukaryotic expression systems. In contrast, we used a bacterial expression system to produce vaccine HA protein (bacterial HA) according to our own design. The HA protein with the sequence of the H5N1 HPAIV strain was efficiently expressed in Escherichia coli, recovered in the form of inclusion bodies and refolded by dilution between two chromatographic purification steps. Antigenicity studies showed that the resulting antigen, referred to as rH5-E. coli, preserves conformational epitopes targeted by antibodies specific for H5-subtype HAs, inhibiting hemagglutination and/or neutralizing influenza viruses in vitro. The proper conformation of this protein and its ability to form functional oligomers were confirmed by a hemagglutination test. Consistent with the biochemical characteristics, prime-boost immunizations with adjuvanted rH5-E. coli protected 100% and 70% of specific pathogen-free, layer-type chickens against challenge with homologous and heterologous H5N1 HPAIVs, respectively. The observed protection was related to the positivity in the FluAC H5 test (IDVet) but not to hemagglutination-inhibiting antibody titers. Due to full protection, the effective contact transmission of the homologous challenge virus did not occur. Survivors from both challenges did not or only transiently shed the viruses, as established by viral RNA detection in oropharyngeal and cloacal swabs. Our results demonstrate that vaccination with rH5-E. coli could confer control of H5N1 HPAIV infection and transmission rates in chicken flocks, accompanied by reduced virus shedding. Moreover, the role of H5 subtype-specific neutralizing antibodies in anti-influenza immunity and a novel correlate of protection are indicated.


  • Open Access

    A novel system for stable, high-level expression from the T7 promoter

    by Malgorzata Kesik-Brodacka, Agnieszka Romanik, Diana Mikiewicz-Sygula, Grazyna Plucienniczak, Andrzej Plucienniczak

    The most widespread, efficient prokaryotic protein-producing system is one where the T7 phage polymerase recognizes the T7 phage promoter (T7 p/p system). Unfortunately, in this system, target protein expression gradually declines and is often undetectable following 3 to 5 subcultures. Although a number of studies have attempted to stabilize the expression levels of the T7 p/p system, none has resolved the problem adequately and thus precludes the use of this system for the production of recombinant proteins on a large scale.